SCHEMBL3012898

SCHEMBL3012898

O=S(=O)(c1ccccc1Cl)N1CCN(c2nc(Cc3ccccc3)cs2)CC1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CHRM4 P08173 7/20 0.47
GBA1 P04062 2/20 0.47
KMT2A Q03164 3/20 0.46
MEN1 O00255 2/20 0.46
LMNA P02545 2/20 0.46
MAPK1 P28482 1/20 0.46
ALDH1A1 P00352 1/20 0.45
MAPT P10636 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
TRPV4 Q9HBA0 1/20 0.42
PIK3CA P42336 1/20 0.41
MTOR P42345 1/20 0.41
RAB9A P51151 1/20 0.41
EPHX2 P34913 2/20 0.41
FAAH O00519 1/20 0.41
CHRM2 P08172 1/20 0.40
CHRM5 P08912 1/20 0.40
CHRM1 P11229 1/20 0.40
CHRM3 P20309 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2997942 0.94 EPHX2 (0.48) CHRM4GBA1KMT2AMEN1LMNA
SCHEMBL3018936 0.93 TSHR (0.46) CHRM4GBA1KMT2AMEN1LMNA
SCHEMBL3018427 0.92 MEN1 (0.46) CHRM4GBA1KMT2AMEN1LMNA
SCHEMBL2999775 0.92 FAAH (0.45) CHRM4GBA1KMT2AMEN1LMNA
SCHEMBL3008268 0.90 CHRM4 (0.45) CHRM4GBA1KMT2AMEN1LMNA
SCHEMBL3015045 0.90 MEN1 (0.44) CHRM4GBA1KMT2AMEN1LMNA
SCHEMBL3018014 0.89 TRPV4 (0.57) KMT2AMEN1LMNAMAPK1ALDH1A1
SCHEMBL3019112 0.89 MAPT (0.44) CHRM4GBA1KMT2AMEN1LMNA
SCHEMBL3023185 0.89 TRPV4 (0.47) KMT2AMEN1LMNAMAPK1ALDH1A1
SCHEMBL3013843 0.89 KMT2A (0.43) CHRM4GBA1KMT2AMEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA CHRM4 4476/4885GBA1 4/4885KMT2A 2680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.